P3 Health Partners lifts 2026 adjusted EBITDA outlook amid structural improvements
P3 Health Partners lifts 2026 adjusted EBITDA outlook amid structural improvements
Overview
US population health manager's Q2 revenue rose 9% yr/yr to $386 mln
Adjusted EBITDA swung to $54 mln profit from a loss a year ago
Company raised full-year 2026 adjusted EBITDA guidance on improved profitability
Outlook
Company raises full-year 2026 adjusted EBITDA guidance to $80 mln-$110 mln
P3 Health Partners sees 2026 revenue of $1.5 bln-$1.6 bln
Company expects 2026 medical margin of $260 mln-$300 mln and medical margin PMPM of $210-$240
Result Drivers
STRUCTURAL IMPROVEMENTS - Co said improved profitability was driven by structural changes in contracts, network, and operating model
NETWORK ECONOMICS - Per-member capitated revenue increased 15% yr/yr, driven by improved network economics, rate progression, and burden of illness performance
FAVORABLE SETTLEMENTS - Medical margin benefited from payer settlements and prior year development recognized in the quarter
Company press release: ID:nBwpnJsja
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $386 mln | $377.95 mln (2 Analysts) |
Q2 Net Income |
| $15.70 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for P3 Health Partners Inc is $14.00, about 20.9% above its August 7 closing price of $11.58
Reuters Recommended Reads
Aug 10 - Accendra Health Q2 profit, revenue miss estimates on large payor exit
Aug 10 - Surgery Partners Q2 revenue beats on growth in same-facility segment
Aug 9 - RadNet raises outlook as Q2 revenue jumps 25%, adjusted EPS beats estimates
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on P3 Health Partners
See all newsBrief: P3 Health Partners Entered SPA With Affiliates Of CPF Pursuant To Which To Issue Up To $70 Million Of Units In Multiple Tranches - SEC Filing
P3 Health Partners Inc reports results for the quarter ended June 30 - Earnings Summary
P3 Health Partners lifts 2026 adjusted EBITDA outlook amid structural improvements
P3 Health Partners Inc expected to post a loss of $1.89 a share - Earnings Preview
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:55 AM